Drug Product
Advanced Modalities
Company Overview
About
BMI Korea is a pharmaceutical CDMO offering comprehensive services.
Key Expertise
Specialized in Quality Control, Stability Testing, Method Development
Therapeutic Areas
Immunology
Rheumatology
Quick Facts
HQ:South Korea
Founded:1997
Employees:219
Capabilities & Services
Core Capabilities
- Peptide Synthesis
- Small Molecule API
- Formulation Development
Types of Organization
GMP Manufacturing
Quality Systems
Regulatory Support
Dosage Forms
Inhalation
Containment Capabilities
Cytotoxic / ADC Handling
Production Scales
Phase II
Clinical
Pilot Scale
Markets Served
North America
Regulatory Approvals
Drug Approval 2RT3JN
Health Canada · #APR-UUJ2XR34 · 2018-03-01
Drug Approval 0EB3J5
FDA · #APR-ZO946IMK · 2021-02-01
Certifications
ISO 9001:2015
International Organization for Standardization
Cert #: CERT-LODKQSU8
Issued: 2020-11-25
Expires: 2025-08-08
ISO 13485:2016
International Organization for Standardization
Cert #: CERT-80STN25E
Issued: 2020-11-23
Expires: 2025-06-07
MHRA GMP
UK Medicines and Healthcare products Regulatory Agency
Cert #: CERT-PTJ0ES9Q
Issued: 2020-05-19
Expires: 2025-05-07
Loading CDMO intelligence...
Key facts about BMI Korea
- BMI Korea is headquartered in South Korea.
- BMI Korea was founded in 1997.
- BMI Korea has 219 employees.
- BMI Korea's capabilities include Peptide Synthesis, Small Molecule API and Formulation Development.
Find CDMOs like BMI Korea
Directory pages this company appears in, each with the full list of matching manufacturers.